USFDA approves Febuxostat tablets by Zydus

The United States Food and Drugs Administration (USFDA) has given final approval to Zydus Lifesciences to market Febuxostat tablets, 40 mg and 80 mg, a statement from Zydus notified.

Febuxostat tablets are indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, the statement said.